Communiqués de presse
(Documents disponibles en anglais seulement)
août 11, 2023
SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER RESULTS: REVENUES UP 3,600%
mai 16, 2023
SUNSHINE BIOPHARMA ANNOUNCES CLOSING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET
mai 12, 2023
SUNSHINE BIOPHARMA ANNOUNCES PRICING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT THE MARKET
mai 11, 2023
SUNSHINE BIOPHARMA REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100%
avr. 05, 2023
SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
févr. 28, 2023
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT
févr. 10, 2023
SUNSHINE BIOPHARMA SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND
jan. 19, 2023
SUNSHINE BIOPHARMA ANNOUNCES SHARE REPURCHASE PROGRAM
déc. 20, 2022
SUNSHINE BIOPHARMA’S ANNUAL LETTER TO SHAREHOLDERS
nov. 16, 2022
SUNSHINE BIOPHARMA ENTERS INTO COLLABORATION WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT
oct. 20, 2022
SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE
juill. 28, 2022
SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA
avr. 28, 2022
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
avr. 26, 2022
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
avr. 25, 2022
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
avr. 05, 2022
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells
mars 14, 2022
Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market
mars 10, 2022
Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market
févr. 25, 2022
SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA
févr. 15, 2022
Sunshine Biopharma Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
déc. 22, 2021
Sunshine Biopharma Announces $1,361,000 in Debt Reduction
nov. 03, 2021
SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS
oct. 06, 2021
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
août 12, 2021
SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN
juill. 27, 2021
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
juill. 20, 2021
SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL
juill. 08, 2021
Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
juin 09, 2021
SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED
mai 20, 2021
SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING
mai 13, 2021
SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING
mai 04, 2021
SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION
avr. 23, 2021
SUNSHINE BIOPHARMA REPORTS FAVORABLE MTD RESULTS FOR COVID-19 TREATMENT
avr. 22, 2021
RB CAPITAL INCREASES INVESTMENT IN SUNSHINE BIOPHARMA
mars 23, 2021
SUNSHINE BIOPHARMA REACHES $2,000,000+ FINANCING FOR CORONAVIRUS TREATMENT
mars 11, 2021
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033
mars 04, 2021
Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a And Initiates QA/QC Testing
mars 01, 2021
Sunshine Biopharma Launches Online Store for Its Science-Based Nutritional Supplements
févr. 18, 2021
Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast
févr. 10, 2021
SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY
févr. 04, 2021
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS
févr. 02, 2021
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033
jan. 27, 2021
SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB
jan. 14, 2021
SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
déc. 22, 2020
SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK
déc. 08, 2020
SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS
déc. 03, 2020
SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET
déc. 01, 2020
SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 plus FINANCING FOR CORONAVIRUS TREATMENT
nov. 24, 2020
SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY
nov. 18, 2020
Sunshine Biopharma Signs An Agreement With A Montreal-Based Company To Advance The Development Of Adva-27a Anticancer Compound
nov. 10, 2020
Sunshine Biopharma Signs an Agreement for Distribution of Essential-9TM in Asia and the Far East
oct. 26, 2020
SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
oct. 19, 2020
SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG
oct. 07, 2020
SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND
sept. 15, 2020
SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
août 25, 2020
SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE
juin 03, 2020
SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT
nov. 06, 2019
SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL CALCIUM-VITAMIN DTM SUPPLEMENT
oct. 17, 2019
SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER<
sept. 03, 2019
Sunshine Biopharma Receives Vegan Certification for Essential 9™ Amino Acids Supplement
mai 28, 2019
In Addition to Essential 9™, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca
mai 16, 2019
Sunshine Biopharma Announces that Essential 9™ is Now Available in the United States on Amazon.com
mars 12, 2019
SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE ON AMAZON.CA
févr. 04, 2019
Sunshine Biopharma Receives Notice Of Allowance For A New Patent Application Extending Protection Of Adva-27a Anticancer Drug Until 2033
déc. 17, 2018
Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company’s First Over The Counter Essential Micronutrient
déc. 12, 2018
Sunshine Biopharma Signs an Agreement With Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug
sept. 14, 2018
Sunshine Biopharma Announces $10 Million Equity Financing
août 16, 2018
Sunshine Biopharma Signs A Service Agreement With Utah Based Quintessential Biosciences Inc.
juin 18, 2018
Sunshine Biopharma Launches Microbiology Testing Service
mai 10, 2018
Sunshine Biopharma Annouces Extension Of The Term Of Its Brokered Up To $10 Million Private Placement Financing
jan. 04, 2018
Sunshine Biopharma Completes the Acquisition of Atlas Pharma
sept. 05, 2017
Sunshine Biopharma Enters Into An Investment Banking Agreement With Jitney Trade To Raise Up To $10 Million For Clinical Trials Of Adva-27a Anticancer Drug
juin 26, 2017
Sunshine Biopharma Releases Results of Independent Valuation
juin 19, 2017
Sunshine Biopharma Files An Application With Health Canada For A Drug Establishment License
jan. 11, 2017
Sunshine Biopharma Currently Reviewing Twenty Three Additional Generic Products For In-licensing
déc. 09, 2016
Sunshine Biopharma Signs Strategic Alliance Agreement With Atlas Pharma
juin 30, 2016
Sunshine Biopharma Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH
mai 11, 2016
Sunshine Biopharma Signs Licensing Agreement For Anastrozole, The Company’s First Generic Drug For Treatment Of Breast Cancer
mars 15, 2016
Sunshine Biopharma Eliminates The Debt Obligations Associated With The Recently Acquired Patents For It’s Adva-27a Anticancer Compound
déc. 28, 2015
Sunshine Biopharma Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound
oct. 09, 2015
Sunshine Biopharma Acquires The US Patent For Its Anticancer Compound, Adva-27a
août 04, 2015
Sunshine Biopharma Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving The Way For Clinical Trials
mai 26, 2015
Sunshine Biopharma To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza In Switzerland
mars 24, 2015
Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India
févr. 25, 2015
Sunshine Biopharma Announces Change To Its Board Of Directors And Officers
jan. 20, 2015
Sunshine Biopharma Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound
nov. 19, 2014
Sunshine Biopharma Signs Agreement With Lonza To Manufacture Its Lead Anticancer Compound, Adva-27a
nov. 03, 2014
Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma’s Lead Anticancer Compound, Adva-27a
oct. 14, 2014
Sunshine Biopharma Retains Renmark Financial Communications To Provide Investor Relations
oct. 01, 2014
Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Completes The Sop’s Required By Health Canada To Secure Drug Establishment License
sept. 03, 2014
Sunshine Biopharma Negotiating With Cro’s To Initiate Master Drug File For Adva-27a Anticancer Compound
août 21, 2014
Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants To Secures Pharmaceutical Establishment License
août 11, 2014
Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Secures Dedicated Space To Commence Global Generic Pharmaceutical Operations
juin 09, 2014
Sunshine Biopharma’s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
mai 12, 2014
Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada
avr. 29, 2014
Sunshine Biopharma Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II
avr. 07, 2014
Sunshine Biopharma Increases The Effectiveness Of Adva-27a Lead Compound 9.5-fold Against Breast And Pancreatic Cancer In Vitro
mars 31, 2014
Management Of Sunshine Biopharma Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise
févr. 14, 2014
Sunshine Biopharma Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a As A Treatment For This Deadly Form Of Cancer
juin 19, 2013
Sunshine Biopharma’s Anticancer Drug Candidate, Adva-27a, Is Unaffected By The Recent Supreme Court Ruling
juin 04, 2013
Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
mai 01, 2013
Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers
avr. 09, 2013
Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
mars 14, 2013
Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant Breast Cancer Drug, Adva-27a
févr. 26, 2013
Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a
jan. 15, 2013
Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a Anticancer Compound
déc. 10, 2012
Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells
déc. 04, 2012
Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a
nov. 27, 2012
Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents
nov. 13, 2012
Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a
oct. 09, 2012
Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a
sept. 25, 2012
Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in Oct. Issue of ANTICANCER RESEARCH
sept. 20, 2012
Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials
sept. 13, 2012
Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a
sept. 04, 2012
Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of the Compound’s Anti-Cancer Activity
août 15, 2012
Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal
août 03, 2012
BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report
juill. 30, 2012
Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a
juill. 24, 2012
Biotech Investor Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a
juill. 19, 2012
Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)
juill. 11, 2012
Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a
juill. 02, 2012
Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound – Adva-27a for Aggressive Forms of Cancer
juin 26, 2012
Sunshine Biopharma’s Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells
mai 22, 2012
Pharmacokinetics Parameters of Sunshine Biopharma’s Lead Anti-Cancer Compound Exceed Expectations
avr. 09, 2012
Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
mars 26, 2012
Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago
nov. 28, 2011
Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals
nov. 15, 2011
Sunshine Biopharma’s Announces Successful Completion of Preclinical Studies for Adva-27a, The Company’s Lead Anti-Cancer Compound
oct. 05, 2011
Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor
août 30, 2011
Clearance of Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate
juill. 27, 2011
Sunshine Biopharma Looking to Mimic Roche’s Billion Dollar Cancer Drug Success
juill. 25, 2011
Sunshine Biopharma’s Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism
juill. 11, 2011
Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells
juin 17, 2011
Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada
avr. 01, 2011
Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com
mars 27, 2011
Sunshine Biopharma’s Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays
mars 04, 2011
CEO CFO Interviews Dr. Steve N. Slilaty
févr. 25, 2011
Interview with Central NY Business Journal
jan. 26, 2011
FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1
jan. 21, 2011
Sunshine Biopharma And Binghamton University (State University Of New York) Enter Into Research Agreement
oct. 26, 2010
CEOCAST Interview with Dr. Steve Slilaty of Sunshine BioPharma Inc.
oct. 13, 2010
Sunshine Biopharma, Inc. Begins Drug Development Activities
oct. 20, 2009
Mountain West Business Solutions Acquires Sunshine Biopharma